| Identification | Back Directory | [Name]
Ocrelizumab | [CAS]
637334-45-3 | [Synonyms]
Ocrelizumab
Research Grade Ocrelizumab(DHC90702) | [Molecular Formula]
C19H16N2O5 |
| Hazard Information | Back Directory | [Uses]
Treatment of rheumatoid arthritis. | [in vivo]
Ocrelizumab (7.5 mg/kg; once daily; 18 days; s.c. or i.v.) inhibits lesions in multiple sclerosis mice by inducing B cell exhaustion through antibody dependent cytotoxicity (ADCC)[1].
Ocrelizumab (50 μg; repeat administration on days 7, 14, and 21; i.v.) can reduce B and T cells in the blood, lymph nodes, and spleen of C57BL/6 mice[2]. | Animal Model: | HuCD20 mice with chronic DTH-TLS lesions[1]. | | Dosage: | 7.5 mg/kg | | Administration: | Subcutaneous injection (s.c.) or intravenous injection (i.v.); once daily; 18 days; initiated on Days 63, 70 and 75 post lesion induction | | Result: | Reduced the number of CD19+ cells and MS like lesions in the spleen and lymph nodes of mice. |
| Animal Model: | C57BL/6 mice [2]. | | Dosage: | 50 μg | | Administration: | Intravenous injection (i.v.); repeat administration on days 7, 14, and 21 | | Result: | Reduced the total CD19+ B cells and CD4, CD8 T cells in the blood, spleen, and LN. |
|
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|